The global IL-1R Agonist market is projected to grow from US$ 656 million in 2024 to US$ 1048 million by 2031, at a CAGR of 7.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

IL-1R Agonist Market

IL-1R agonists refer to a class of compounds or molecules that activate the interleukin-1 receptor (IL-1R). IL-1R is a cell surface receptor that, after binding to IL-1 and other cytokines, can initiate a series of signaling pathways and participate in regulating biological processes such as immune and inflammatory responses. IL-1R agonists are widely used in medical research and can be used to simulate the activation of the IL-1 signaling pathway and study its mechanism of action in inflammation, immune response, infection, and autoimmune diseases.

The IL-1R agonist market is currently in a stage of rapid development, mainly due to its wide application in biomedical research and clinical treatment. IL-1R agonists are widely used to study biological processes such as inflammation, immune regulation, and tumors. Scientific researchers use IL-1R agonists to explore the mechanisms of disease and provide a theoretical basis for the development of new drugs. With the deepening of scientific research, the demand for IL-1R agonists is also increasing, driving the market to continue to expand. In summary, the IL-1R agonist market has broad development prospects and huge market potential.

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global IL-1R Agonist market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.

Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of IL-1R Agonist Market Report

Report Metric	Details
Report Name	IL-1R Agonist Market
Accounted market size in 2024	US$ 656 million
Forecasted market size in 2031	US$ 1048 million
CAGR	7.0%
Base Year	2024
Forecasted years	2025 - 2031
Segment by Type	Naturally Extracted Synthetic
Segment by Application	Biomedical Industry Immunology Research Cancer Research
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Abcam, R&D Systems, Novus Biologicals, Cell Signaling Technology, BioLegend, Merck, Thermo Fisher Scientific, Cayman Chemical, PeproTech, BGI Genomics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the IL-1R Agonist study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

How fast is IL-1R Agonist Market growing?

Ans: The IL-1R Agonist Market witnessing a CAGR of 7.0% during the forecast period 2025-2031.

What is the IL-1R Agonist Market size in 2031?

Ans: The IL-1R Agonist Market size in 2031 will be US$ 1048 million.

Who are the main players in the IL-1R Agonist Market report?

Ans: The main players in the IL-1R Agonist Market are Abcam, R&D Systems, Novus Biologicals, Cell Signaling Technology, BioLegend, Merck, Thermo Fisher Scientific, Cayman Chemical, PeproTech, BGI Genomics

What are the Application segmentation covered in the IL-1R Agonist Market report?

Ans: The Applications covered in the IL-1R Agonist Market report are Biomedical Industry, Immunology Research, Cancer Research

What are the Type segmentation covered in the IL-1R Agonist Market report?

Ans: The Types covered in the IL-1R Agonist Market report are Naturally Extracted, Synthetic

1 Study Coverage

1.1 Introduction to IL-1R Agonist: Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global IL-1R Agonist Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Naturally Extracted

1.2.3 Synthetic

1.3 Market Segmentation by Application

1.3.1 Global IL-1R Agonist Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Biomedical Industry

1.3.3 Immunology Research

1.3.4 Cancer Research

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global IL-1R Agonist Revenue Estimates and Forecasts 2020-2031

2.2 Global IL-1R Agonist Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020--2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.3 Global IL-1R Agonist Sales Estimates and Forecasts 2020-2031

2.4 Global IL-1R Agonist Sales by Region

2.4.1 Sales Comparison: 2020 VS 2024 VS 2031

2.4.2 Historical and Forecasted Sales by Region (2020-2031)

2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends

2.4.4 Global Sales Market Share by Region (2020-2031)

3 Competition by Manufacturers

3.1 Global IL-1R Agonist Sales by Manufacturers

3.1.1 Global Sales Volume by Manufacturers (2020-2025)

3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)

3.2 Global IL-1R Agonist Manufacturer Revenue Rankings and Tiers

3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)

3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)

3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.3 Manufacturer Profitability Profiles and Pricing Strategies

3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)

3.3.2 Manufacturer-Level Price Trends (2020-2025)

3.4 Key Manufacturers Manufacturing Base and Headquarters

3.5 Main Product Type Market Size by Manufacturers

3.5.1 Naturally Extracted Market Size by Manufacturers

3.5.2 Synthetic Market Size by Manufacturers

3.6 Global IL-1R Agonist Market Concentration and Dynamics

3.6.1 Global Market Concentration (CR5 and HHI)

3.6.2 Entrant/Exit Impact Analysis

3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global IL-1R Agonist Sales Performance by Type

4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)

4.1.2 Global Sales Market Share by Type (2020-2031)

4.2 Global IL-1R Agonist Revenue Trends by Type

4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.2.2 Global Revenue Market Share by Type (2020-2031)

4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)

4.4 Product Technology Differentiation

4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.5.1 High-Growth Niches and Adoption Drivers

4.5.2 Profitability Hotspots and Cost Drivers

4.5.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global IL-1R Agonist Sales by Application

5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)

5.1.2 Global Sales Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Global IL-1R Agonist Revenue by Application

5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.2.2 Revenue Market Share by Application (2020-2031)

5.3 Global Pricing Dynamics by Application (2020-2031)

5.4 Downstream Customer Analysis

5.4.1 Top Customers by Region

5.4.2 Top Customers by Application

6 North America

6.1 North America Sales Volume and Revenue (2020-2031)

6.2 North America Key Manufacturers Sales Revenue in 2024

6.3 North America IL-1R Agonist Sales and Revenue by Type (2020-2031)

6.4 North America IL-1R Agonist Sales and Revenue by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America IL-1R Agonist Market Size by Country

6.6.1 North America Revenue by Country

6.6.2 North America Sales Trends by Country

6.6.3 US

6.6.4 Canada

6.6.5 Mexico

7 Europe

7.1 Europe Sales Volume and Revenue (2020-2031)

7.2 Europe Key Manufacturers Sales Revenue in 2024

7.3 Europe IL-1R Agonist Sales and Revenue by Type (2020-2031)

7.4 Europe IL-1R Agonist Sales and Revenue by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe IL-1R Agonist Market Size by Country

7.6.1 Europe Revenue by Country

7.6.2 Europe Sales Trends by Country

7.6.3 Germany

7.6.4 France

7.6.5 U.K.

7.6.6 Italy

7.6.7 Russia

8 Asia-Pacific

8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)

8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024

8.3 Asia-Pacific IL-1R Agonist Sales and Revenue by Type (2020-2031)

8.4 Asia-Pacific IL-1R Agonist Sales and Revenue by Application (2020-2031)

8.5 Asia-Pacific IL-1R Agonist Market Size by Region

8.5.1 Asia-Pacific Revenue by Region

8.5.2 Asia-Pacific Sales Trends by Region

8.6 Asia-Pacific Growth Accelerators and Market Barriers

8.7 Southeast Asia

8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)

8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines

8.8 China

8.9 Japan

8.10 South Korea

8.11 China Taiwan

8.12 India

9 Central and South America

9.1 Central and South America Sales Volume and Revenue (2020-2031)

9.2 Central and South America Key Manufacturers Sales Revenue in 2024

9.3 Central and South America IL-1R Agonist Sales and Revenue by Type (2020-2031)

9.4 Central and South America IL-1R Agonist Sales and Revenue by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America IL-1R Agonist Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)

10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024

10.3 Middle East and Africa IL-1R Agonist Sales and Revenue by Type (2020-2031)

10.4 Middle East and Africa IL-1R Agonist Sales and Revenue by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa IL-1R Agonist Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Turkey

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Abcam

11.1.1 Abcam Corporation Information

11.1.2 Abcam Business Overview

11.1.3 Abcam IL-1R Agonist Product Models, Descriptions and Specifications

11.1.4 Abcam IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.1.5 Abcam IL-1R Agonist Sales by Product in 2024

11.1.6 Abcam IL-1R Agonist Sales by Application in 2024

11.1.7 Abcam IL-1R Agonist Sales by Geographic Area in 2024

11.1.8 Abcam IL-1R Agonist SWOT Analysis

11.1.9 Abcam Recent Developments

11.2 R&D Systems

11.2.1 R&D Systems Corporation Information

11.2.2 R&D Systems Business Overview

11.2.3 R&D Systems IL-1R Agonist Product Models, Descriptions and Specifications

11.2.4 R&D Systems IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.2.5 R&D Systems IL-1R Agonist Sales by Product in 2024

11.2.6 R&D Systems IL-1R Agonist Sales by Application in 2024

11.2.7 R&D Systems IL-1R Agonist Sales by Geographic Area in 2024

11.2.8 R&D Systems IL-1R Agonist SWOT Analysis

11.2.9 R&D Systems Recent Developments

11.3 Novus Biologicals

11.3.1 Novus Biologicals Corporation Information

11.3.2 Novus Biologicals Business Overview

11.3.3 Novus Biologicals IL-1R Agonist Product Models, Descriptions and Specifications

11.3.4 Novus Biologicals IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.3.5 Novus Biologicals IL-1R Agonist Sales by Product in 2024

11.3.6 Novus Biologicals IL-1R Agonist Sales by Application in 2024

11.3.7 Novus Biologicals IL-1R Agonist Sales by Geographic Area in 2024

11.3.8 Novus Biologicals IL-1R Agonist SWOT Analysis

11.3.9 Novus Biologicals Recent Developments

11.4 Cell Signaling Technology

11.4.1 Cell Signaling Technology Corporation Information

11.4.2 Cell Signaling Technology Business Overview

11.4.3 Cell Signaling Technology IL-1R Agonist Product Models, Descriptions and Specifications

11.4.4 Cell Signaling Technology IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.4.5 Cell Signaling Technology IL-1R Agonist Sales by Product in 2024

11.4.6 Cell Signaling Technology IL-1R Agonist Sales by Application in 2024

11.4.7 Cell Signaling Technology IL-1R Agonist Sales by Geographic Area in 2024

11.4.8 Cell Signaling Technology IL-1R Agonist SWOT Analysis

11.4.9 Cell Signaling Technology Recent Developments

11.5 BioLegend

11.5.1 BioLegend Corporation Information

11.5.2 BioLegend Business Overview

11.5.3 BioLegend IL-1R Agonist Product Models, Descriptions and Specifications

11.5.4 BioLegend IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.5.5 BioLegend IL-1R Agonist Sales by Product in 2024

11.5.6 BioLegend IL-1R Agonist Sales by Application in 2024

11.5.7 BioLegend IL-1R Agonist Sales by Geographic Area in 2024

11.5.8 BioLegend IL-1R Agonist SWOT Analysis

11.5.9 BioLegend Recent Developments

11.6 Merck

11.6.1 Merck Corporation Information

11.6.2 Merck Business Overview

11.6.3 Merck IL-1R Agonist Product Models, Descriptions and Specifications

11.6.4 Merck IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.6.5 Merck Recent Developments

11.7 Thermo Fisher Scientific

11.7.1 Thermo Fisher Scientific Corporation Information

11.7.2 Thermo Fisher Scientific Business Overview

11.7.3 Thermo Fisher Scientific IL-1R Agonist Product Models, Descriptions and Specifications

11.7.4 Thermo Fisher Scientific IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.7.5 Thermo Fisher Scientific Recent Developments

11.8 Cayman Chemical

11.8.1 Cayman Chemical Corporation Information

11.8.2 Cayman Chemical Business Overview

11.8.3 Cayman Chemical IL-1R Agonist Product Models, Descriptions and Specifications

11.8.4 Cayman Chemical IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.8.5 Cayman Chemical Recent Developments

11.9 PeproTech

11.9.1 PeproTech Corporation Information

11.9.2 PeproTech Business Overview

11.9.3 PeproTech IL-1R Agonist Product Models, Descriptions and Specifications

11.9.4 PeproTech IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.9.5 PeproTech Recent Developments

11.10 BGI Genomics

11.10.1 BGI Genomics Corporation Information

11.10.2 BGI Genomics Business Overview

11.10.3 BGI Genomics IL-1R Agonist Product Models, Descriptions and Specifications

11.10.4 BGI Genomics IL-1R Agonist Sales, Price, Revenue and Gross Margin (2020-2025)

11.10.5 BGI Genomics Recent Developments

12 Value Chain and Supply-Chain Analysis

12.1 IL-1R Agonist Industry Chain

12.2 IL-1R Agonist Upstream Materials Analysis

12.2.1 Raw Materials

12.2.2 Key Suppliers Market Share & Risk Assessment

12.3 IL-1R Agonist Integrated Production Analysis

12.3.1 Manufacturing Footprint Analysis

12.3.2 Regional Production Market Share (2020-2031)

12.3.3 Regulatory and Trade Policy Impact on Production

12.3.4 Production Technology Overview

12.3.5 Regional Cost Drivers

12.4 IL-1R Agonist Sales Channels and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 IL-1R Agonist Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global IL-1R Agonist Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Abcam

R&D Systems

Novus Biologicals

Cell Signaling Technology

BioLegend

Merck

Thermo Fisher Scientific

Cayman Chemical

PeproTech

BGI Genomics

List of Tables

Table 1. Global IL-1R Agonist Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global IL-1R Agonist Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global IL-1R Agonist Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global IL-1R Agonist Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global IL-1R Agonist Revenue by Region (2026-2031) & (US$ Million)

Table 6. Global IL-1R Agonist Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)

Table 7. Global IL-1R Agonist Sales by Region (2020-2025) & (K Units)

Table 8. Global IL-1R Agonist Sales by Region (2026-2031) & (K Units)

Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 10. Global IL-1R Agonist Sales by Manufacturers (2020-2025) & (K Units)

Table 11. Global IL-1R Agonist Sales Share by Manufacturers (2020-2025)

Table 12. Global IL-1R Agonist Revenue by Manufacturers (2020-2025) & (US$ Million)

Table 13. Global IL-1R Agonist Revenue Market Share by Manufacturers (2020-2025)

Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 15. Global IL-1R Agonist by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IL-1R Agonist as of 2024)

Table 16. Global IL-1R Agonist Average Gross Margin (%) by Manufacturer (2020 VS 2024)

Table 17. Global IL-1R Agonist Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)

Table 18. Key Manufacturers IL-1R Agonist Manufacturing Base and Headquarters

Table 19. Global IL-1R Agonist Market Concentration Ratio (CR5 and HHI)

Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 22. Global IL-1R Agonist Sales by Type (2020-2025) & (K Units)

Table 23. Global IL-1R Agonist Sales by Type (2026-2031) & (K Units)

Table 24. Global IL-1R Agonist Revenue by Type (2020-2025) & (US$ Million)

Table 25. Global IL-1R Agonist Revenue by Type (2026-2031) & (US$ Million)

Table 26. Global IL-1R Agonist ASP by Type (2020-2031) & (US$/Unit)

Table 27. Technical Specifications by Key Product Type

Table 28. Global IL-1R Agonist Sales by Application (2020-2025) & (K Units)

Table 29. Global IL-1R Agonist Sales by Application (2026-2031) & (K Units)

Table 30. IL-1R Agonist High-Growth Sectors Demand CAGR (2024-2031)

Table 31. Global IL-1R Agonist Revenue by Application (2020-2025) & (US$ Million)

Table 32. Global IL-1R Agonist Revenue by Application (2026-2031) & (US$ Million)

Table 33. Global IL-1R Agonist ASP by Application (2020-2031) & (US$/Unit)

Table 34. Top Customers by Region

Table 35. Top Customers by Application

Table 36. North America IL-1R Agonist Growth Accelerators and Market Barriers

Table 37. North America IL-1R Agonist Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 38. North America IL-1R Agonist Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 39. Europe IL-1R Agonist Growth Accelerators and Market Barriers

Table 40. Europe IL-1R Agonist Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Europe IL-1R Agonist Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 42. Asia-Pacific IL-1R Agonist Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 43. Asia-Pacific IL-1R Agonist Sales (K Units) by Country (2020 VS 2024 VS 2031)

Table 44. Asia-Pacific IL-1R Agonist Growth Accelerators and Market Barriers

Table 45. Southeast Asia IL-1R Agonist Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Central and South America IL-1R Agonist Investment Opportunities and Key Challenges

Table 47. Central and South America IL-1R Agonist Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 48. Middle East and Africa IL-1R Agonist Investment Opportunities and Key Challenges

Table 49. Middle East and Africa IL-1R Agonist Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 50. Abcam Corporation Information

Table 51. Abcam Description and Major Businesses

Table 52. Abcam Product Models, Descriptions and Specifications

Table 53. Abcam Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 54. Abcam Sales Value Proportion by Product in 2024

Table 55. Abcam Sales Value Proportion by Application in 2024

Table 56. Abcam Sales Value Proportion by Geographic Area in 2024

Table 57. Abcam IL-1R Agonist SWOT Analysis

Table 58. Abcam Recent Developments

Table 59. R&D Systems Corporation Information

Table 60. R&D Systems Description and Major Businesses

Table 61. R&D Systems Product Models, Descriptions and Specifications

Table 62. R&D Systems Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 63. R&D Systems Sales Value Proportion by Product in 2024

Table 64. R&D Systems Sales Value Proportion by Application in 2024

Table 65. R&D Systems Sales Value Proportion by Geographic Area in 2024

Table 66. R&D Systems IL-1R Agonist SWOT Analysis

Table 67. R&D Systems Recent Developments

Table 68. Novus Biologicals Corporation Information

Table 69. Novus Biologicals Description and Major Businesses

Table 70. Novus Biologicals Product Models, Descriptions and Specifications

Table 71. Novus Biologicals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 72. Novus Biologicals Sales Value Proportion by Product in 2024

Table 73. Novus Biologicals Sales Value Proportion by Application in 2024

Table 74. Novus Biologicals Sales Value Proportion by Geographic Area in 2024

Table 75. Novus Biologicals IL-1R Agonist SWOT Analysis

Table 76. Novus Biologicals Recent Developments

Table 77. Cell Signaling Technology Corporation Information

Table 78. Cell Signaling Technology Description and Major Businesses

Table 79. Cell Signaling Technology Product Models, Descriptions and Specifications

Table 80. Cell Signaling Technology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 81. Cell Signaling Technology Sales Value Proportion by Product in 2024

Table 82. Cell Signaling Technology Sales Value Proportion by Application in 2024

Table 83. Cell Signaling Technology Sales Value Proportion by Geographic Area in 2024

Table 84. Cell Signaling Technology IL-1R Agonist SWOT Analysis

Table 85. Cell Signaling Technology Recent Developments

Table 86. BioLegend Corporation Information

Table 87. BioLegend Description and Major Businesses

Table 88. BioLegend Product Models, Descriptions and Specifications

Table 89. BioLegend Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 90. BioLegend Sales Value Proportion by Product in 2024

Table 91. BioLegend Sales Value Proportion by Application in 2024

Table 92. BioLegend Sales Value Proportion by Geographic Area in 2024

Table 93. BioLegend IL-1R Agonist SWOT Analysis

Table 94. BioLegend Recent Developments

Table 95. Merck Corporation Information

Table 96. Merck Description and Major Businesses

Table 97. Merck Product Models, Descriptions and Specifications

Table 98. Merck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 99. Merck Recent Developments

Table 100. Thermo Fisher Scientific Corporation Information

Table 101. Thermo Fisher Scientific Description and Major Businesses

Table 102. Thermo Fisher Scientific Product Models, Descriptions and Specifications

Table 103. Thermo Fisher Scientific Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 104. Thermo Fisher Scientific Recent Developments

Table 105. Cayman Chemical Corporation Information

Table 106. Cayman Chemical Description and Major Businesses

Table 107. Cayman Chemical Product Models, Descriptions and Specifications

Table 108. Cayman Chemical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 109. Cayman Chemical Recent Developments

Table 110. PeproTech Corporation Information

Table 111. PeproTech Description and Major Businesses

Table 112. PeproTech Product Models, Descriptions and Specifications

Table 113. PeproTech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 114. PeproTech Recent Developments

Table 115. BGI Genomics Corporation Information

Table 116. BGI Genomics Description and Major Businesses

Table 117. BGI Genomics Product Models, Descriptions and Specifications

Table 118. BGI Genomics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 119. BGI Genomics Recent Developments

Table 120. Key Raw Materials Distribution

Table 121. Raw Materials Key Suppliers

Table 122. Critical Raw Material Supplier Concentration (2024) & Risk Index

Table 123. Milestones in Production Technology Evolution

Table 124. Distributors List

Table 125. Market Trends and Market Evolution

Table 126. Market Drivers and Opportunities

Table 127. Market Challenges, Risks, and Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. IL-1R Agonist Product Picture

Figure 2. Global IL-1R Agonist Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Naturally Extracted Product Picture

Figure 4. Synthetic Product Picture

Figure 5. Global IL-1R Agonist Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Biomedical Industry

Figure 7. Immunology Research

Figure 8. Cancer Research

Figure 9. IL-1R Agonist Report Years Considered

Figure 10. Global IL-1R Agonist Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 12. Global IL-1R Agonist Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global IL-1R Agonist Revenue Market Share by Region (2020-2031)

Figure 14. Global IL-1R Agonist Sales (2020-2031) & (K Units)

Figure 15. Global IL-1R Agonist Sales (CAGR) by Region (2020-2031) (K Units)

Figure 16. Global IL-1R Agonist Sales Market Share by Region (2020-2031)

Figure 17. Top 5 and Top 10 Manufacturers IL-1R Agonist Sales Volume Market Share in 2024

Figure 18. Global IL-1R Agonist Revenue Market Share Ranking (2024)

Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 20. Naturally Extracted Revenue Market Share by Manufacturer in 2024

Figure 21. Synthetic Revenue Market Share by Manufacturer in 2024

Figure 22. Global IL-1R Agonist Sales Market Share by Type (2020-2031)

Figure 23. Global IL-1R Agonist Revenue Market Share by Type (2020-2031)

Figure 24. Global IL-1R Agonist Sales Market Share by Application (2020-2031)

Figure 25. Global IL-1R Agonist Revenue Market Share by Application (2020-2031)

Figure 26. North America IL-1R Agonist Sales YoY (2020-2031) & (K Units)

Figure 27. North America IL-1R Agonist Revenue YoY (2020-2031) & (US$ Million)

Figure 28. North America Top 5 Manufacturers IL-1R Agonist Sales Revenue (US$ Million) in 2024

Figure 29. North America IL-1R Agonist Sales Volume (K Units) by Type (2020- 2031)

Figure 30. North America IL-1R Agonist Sales Revenue (US$ Million) by Type (2020 - 2031)

Figure 31. North America IL-1R Agonist Sales Volume (K Units) by Application (2020-2031)

Figure 32. North America IL-1R Agonist Sales Revenue (US$ Million) by Application (2020-2031)

Figure 33. US IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 34. Canada IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 35. Mexico IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 36. Europe IL-1R Agonist Sales YoY (2020-2031) & (K Units)

Figure 37. Europe IL-1R Agonist Revenue YoY (2020-2031) & (US$ Million)

Figure 38. Europe Top 5 Manufacturers IL-1R Agonist Sales Revenue (US$ Million) in 2024

Figure 39. Europe IL-1R Agonist Sales Volume (K Units) by Type (2020-2031)

Figure 40. Europe IL-1R Agonist Sales Revenue (US$ Million) by Type (2020-2031)

Figure 41. Europe IL-1R Agonist Sales Volume (K Units) by Application (2020-2031)

Figure 42. Europe IL-1R Agonist Sales Revenue (US$ Million) by Application (2020-2031)

Figure 43. Germany IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 44. France IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 45. U.K. IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 46. Italy IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 47. Russia IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 48. Asia-Pacific IL-1R Agonist Sales YoY (2020-2031) & (K Units)

Figure 49. Asia-Pacific IL-1R Agonist Revenue YoY (2020-2031) & (US$ Million)

Figure 50. Asia-Pacific Top 8 Manufacturers IL-1R Agonist Sales Revenue (US$ Million) in 2024

Figure 51. Asia-Pacific IL-1R Agonist Sales Volume (K Units) by Type (2020- 2031)

Figure 52. Asia-Pacific IL-1R Agonist Sales Revenue (US$ Million) by Type (2020- 2031)

Figure 53. Asia-Pacific IL-1R Agonist Sales Volume (K Units) by Application (2020-2031)

Figure 54. Asia-Pacific IL-1R Agonist Sales Revenue (US$ Million) by Application (2020-2031)

Figure 55. Indonesia IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 56. Japan IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 57. South Korea IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 58. China Taiwan IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 59. India IL-1R Agonist Revenue (2020-2031) & (US$ Million)

Figure 60. Central and South America IL-1R Agonist Sales YoY (2020-2031) & (K Units)

Figure 61. Central and South America IL-1R Agonist Revenue YoY (2020-2031) & (US$ Million)

Figure 62. Central and South America Top 5 Manufacturers IL-1R Agonist Sales Revenue (US$ Million) in 2024

Figure 63. Central and South America IL-1R Agonist Sales Volume (K Units) by Type (2021-2031)

Figure 64. Central and South America IL-1R Agonist Sales Revenue (US$ Million) by Type (2020-2031)

Figure 65. Central and South America IL-1R Agonist Sales Volume (K Units) by Application (2020-2031)

Figure 66. Central and South America IL-1R Agonist Sales Revenue (US$ Million) by Application (2020-2031)

Figure 67. Brazil IL-1R Agonist Revenue (2020-2025) & (US$ Million)

Figure 68. Argentina IL-1R Agonist Revenue (2020-2025) & (US$ Million)

Figure 69. Middle East, and Africa IL-1R Agonist Sales YoY (2020-2031) & (K Units)

Figure 70. Middle East and Africa IL-1R Agonist Revenue YoY (2020-2031) & (US$ Million)

Figure 71. Middle East and Africa Top 5 Manufacturers IL-1R Agonist Sales Revenue (US$ Million) in 2024

Figure 72. Middle East and Africa IL-1R Agonist Sales Volume (K Units) by Type (2021-2031)

Figure 73. South America IL-1R Agonist Sales Revenue (US$ Million) by Type (2020-2031)

Figure 74. Middle East and Africa IL-1R Agonist Sales Volume (K Units) by Application (2020-2031)

Figure 75. Middle East and Africa IL-1R Agonist Sales Revenue (US$ Million) by Application (2020-2031)

Figure 76. GCC Countries IL-1R Agonist Revenue (2020-2025) & (US$ Million)

Figure 77. Turkey IL-1R Agonist Revenue (2020-2025) & (US$ Million)

Figure 78. Egypt IL-1R Agonist Revenue (2020-2025) & (US$ Million)

Figure 79. South Africa IL-1R Agonist Revenue (2020-2025) & (US$ Million)

Figure 80. IL-1R Agonist Industry Chain Mapping

Figure 81. Regional IL-1R Agonist Manufacturing Base Distribution (%)

Figure 82. Global IL-1R Agonist Production Market Share by Region (2020-2031)

Figure 83. IL-1R Agonist Production Process

Figure 84. Regional IL-1R Agonist Production Cost Structure

Figure 85. Channels of Distribution (Direct Vs Distribution)

Figure 86. Bottom-up and Top-down Approaches for This Report

Figure 87. Data Triangulation

Figure 88. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global IL 6R ELISA Kit Market Research Report 2024

Global IL 2R Inhibitors Market Research Report 2024

Global THR β Agonists Market Research Report 2024

Global Interleukin 6 Inhibitors for Rheumatoid Arthritis Market Research Report 2024

Global IL 23 Receptor Antagonist Market Research Report 2024

Global γ Aminobutyric Acid Receptor Agonists Market Research Report 2025

Global IL 6 Inhibitors Market Research Report 2024

Global GABAA Receptor Agonists Market Research Report 2025

Global GABAB Receptor Agonists Market Research Report 2025

Global Dopamine Receptor Agonists Market Research Report 2025

Global Melanocortin Agonist Market Research Report 2024

Global Melanocortin Receptor Agonist Drugs Market Research Report 2024

Global Vitamin D Receptor VDR or Calcitriol Receptor Agonist Market Research Report 2024

Opioid Receptor Agonist Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Dopamine Receptor Agonists For PD Market Research Report 2025

Global GIP 1 Receptor Agonist Market Research Report 2024

Global Novel Benzodiazepine Receptor Agonists Market Research Report 2025

Global Long acting Melatonin Receptor Agonists Market Research Report 2025

Global GLP 1 Receptor Agonist Drugs Market Research Report 2024

RELATED REPORTS

Global Pharmacy Chatbot Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-10T20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Inline Pharmaceutical Packaging Leak Detection System Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-6Q20319

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Radiological Marker Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-35Z19949

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

Global Pharmaceutical Biomanufacturing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-26E19785

Wed Dec 03 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions